England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...

The NHS in England will be the first health system in the world to roll-out a ‘trojan horse’ targeted therapy for blood cancer patients which could halt the disease’s progression by nearly three times ...

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

A “Trojan horse” therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world ...

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

ISB 2001, a first-in-class trispecific antibody developed by IGI, showed a 79% response rate in relapsed/refractory multiple ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...